Organ Transplant Immunosuppressant Drugs Market

Report Description
Table of Contents

Report Description

The global organ transplant immunosuppressant drugs market is estimated to be USD 4,981.7 million in 2021 and is expected to witness a CAGR of 3.71% during the forecast period. Rising incidence of chronic ailments, demand for transplantation procedures such as kidney, liver, and heart transplant, along with technological advancements are the major factors driving the global organ transplant immunosuppressant drugs market. However, various factors such as high cost of transplantation as it requires a highly skilled individual along with best tools available makes this process very expensive and low availability of organs as the number of individuals donating their organs are less in number thus these factors are hindering the market growth.

Global Organ Transplant Immunosuppressant Drugs Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Drug Class

On the basis of drug class, the market is segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitor, steroids, and antibodies. In 2021, calcineurin inhibitors segment accounted for the largest revenue share and is expected to maintain the dominance during the forecast period. This is attributed to the affordability of the drug and high adoption among the medical practitioners. The antibodies segment is anticipated to grow at a lucrative CAGR during the forecast period owing to an increase in number of pipeline studies for organ transplant rejection.

By Transplant Type

On the basis of transplant type, the market has been segmented into the liver, kidney, heart, pancreas, lung, and other transplants. In 2021, the kidney segment accounted for the largest market share and is expected to lead the market during the forecast period. This can be attributed to increasing demand and comparatively better organ availability than other transplants. The lung transplant segment is anticipated to grow at a steady CAGR during the forecast period owing to rising research and development activities in the area.

By Distribution Channel

On the basis of the distribution channel, the market is segmented into hospital pharmacies market, retail pharmacies market, and online pharmacies market. Hospital and retail pharmacies market segment accounts for the majority of the market share in the organ transplant immunosuppressant drugs market in 2021. This major share of the market is because of the necessity to improve the efficiency and high penetration in these channels.

Regional Insights

North America dominated the global organ transplant immunosuppressant drugs market in 2021. Increase healthcare spending, well established R&D infrastructure, positive healthcare reimbursement policies, and huge demand for organ transplants are the factors driving the market in this region. Asia Pacific region showed the fastest CAGR during the forecast period. Promising initiatives about the investments by the governments and manufacturers in the healthcare sector and plenty of unexplored opportunities are the key factors propelling the growth in this region.

Competitor Insights

Some of the major companies in the market are Astellas Pharma(Japan), Sanofi Genzyme (France), Accord Healthcare Ltd. (India), Novartis AG (Switzerland), Mylan Laboratories, Inc. (U.S.), Dr. Reddy’s Laboratories Ltd.(India), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (U.K.), Veloxis Pharmaceuticals A/S (Denmark), and Bristol-Myers Squibb Company (U.S.). Increase in research & development, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The organ transplant immunosuppressant drugs market report is categorized into the following segments and subsegments: